Boston Scientific lifts FY25 outlook amid continued cardiovascular boom

Boston Scientific has lifted its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid continued strong performance in its third quarter (Q3), largely driven by growth in its cardiovascular business.

The company now expects profits of $3.02 and $3.04 per share for FY25, up from $2.95 to $2.99 previously.

Following the Q3 result’s announcement, Boston’s share price on the New York Stock Exchange (NYSE) rose by more than 4% to around $104 per share, up from $103.10 at market open on 22 October. Boston has a market cap of around $153bn.

With continued uptake of its Farapulse pulsed-field ablation (PFA) system, the FY25 uplift reflects Boston’s second full year profit uplift in 2025, having previously raised its profit expectations for 2025 from $2.87 to $2.94 per share following Q2 results.

Boston’s financials revealed total sales of more than $5bn in Q3 2025, reflecting a 20.4% rise versus $4.2bn in Q3 2024.

Much of the total revenue was attributable to growth in Boston’s cardiovascular portfolio, with revenue exceeding $3.3bn, indicative of a 22.4% rise from $2.7bn in Q3 2024.

During a post-earnings conference call, Boston’s CEO Mike Mahoney shared that 500,000 patients to date have been treated with Farapulse, with “consistent and reproducible real-world results”.

He commented: “Continued strong double-digit growth in Farapulse is supported by ramping adoption of our OPAL HDx Mapping System, with one in three Farapulse accounts now utilising our integrated FARAWAVE NAV PFA catheter and OPAL device.”

Rival medtech company Medtronic recently lifted its FY26 profit outlook to between $5.60 and $5.66 per share after the cardiac rhythm and heart failure segment within its cardiovascular portfolio climbed to around $1.7bn in Q1 2026, denoting an 11.5% rise on $1.53bn in Q1 of FY26.

The uplift for Medtronic reflects the ongoing adoption of its Affera mapping and ablation system featuring the Sphere-9 Catheter, and PulseSelect PFA for the treatment of atrial fibrillation (AFib). Competing for market share against Boston’s Farapulse PFA, PulseSelect gained US Food and Drug Administration (FDA) clearance in December 2023, ahead of Farapulse’s clearance from the agency in January 2024.

Elsewhere across the business, revenue in Boston’s MedSurg portfolio swelled to around $1.7bn, denoting a 16.4% rise on Q3 2024, with Boston’s urology segment rising by 28.1% to $682m. The neuromodulation segment within Boston’s MedSurg portfolio grew by 9.1% to $293m.

In Boston’s earnings call, Mahoney highlighted that the company expects the recent $533m acquisition of Nalu Medical to complement the company’s commercial strength within the interventional pain segment.

Story Continues

Designed to address chronic pain in regions such as the shoulder and lower back via peripheral nerve stimulation (PNS), Nalu’s neurostimulation system adds to Boston’s existing pain management therapies in spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation.

"Boston Scientific lifts FY25 outlook amid continued cardiovascular boom" was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

View Comments